HELP
NASD Helus Pharma Inc.$10.51 ↑ +0.00 (+0.00%) Trading Up from the previous close of $10.51, $0.30 below the day’s high of $10.81
- YTD change
- +35.96%
- vs 20-day SMA
- -17.58%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
+5.26 (+100.19%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 30.6% away from all-time highs of $15.15
- HELP is up 36% since the beginning of the year
- HELP is up 36% over the past 12 months
- HELP is down 15% over the past 1 month
- 4% of all HELP investors are betting against HELP
HELP reads not so good: the 12-month move is +36.0%.
- Previous minute
- +$0.00
- Last hour
- -$0.07
- Last 5 days
- -17.24%
- vs 8-day SMA
- -12.40%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.